MEDIX, God. 15 Br. 82  •  Sponzorirani članak  •  Interna medicina HR ENG

Novi antagonist angiotenzinskih receptora tipa 1 dostupan u Hrvatskoj za liječenje bolesnika s hipertenzijom i zatajenjem srcaNew angiotensin II type 1 receptor blocker antagonist indicated for treatment of patients with hypertension and heart failure now available in Croatia

Darko Počanić

Liječenje hipertenzije i kongestivnog zatajenja srca antagonistima angiotenzinskih receptora tipa 1 (ARB) već je etablirano u kliničkoj praksi. Kandesartan cileksetil noviji je ARB koji ima dokazano dobar antihipertenzivni učinak, usporediv s terapijom antagonistima kalcijevih kanala, a učinkovitiji od usporednih lijekova iz skupine ARB. Uz vrlo malo nuspojava, čija incidencija je usporediva s placebom, u kliničkoj primjeni, samostalno ili u kombinaciji s diuretikom, postiže učinkovitu kontrolu krvnog tlaka, uz povoljan učinak na kardiovaskularni sustav. Testiran kod kongestivnog zatajenja srca, ne samo umjesto inhibitora angiotenzin konvertirajućeg enzima (ACEI), već kao nadopuna terapiji ACEI i kod pacijenata sa oštećenom dijastoličkom, a sačuvanom sistoličkom funkcijom lijeve klijetke, dokazano smanjuje kardiovaskularne komplikacije i broj hospitalizacija

Ključne riječi:
antagonisti angiotenzinskih receptora tipa 1; hipertenzija; kandesartan cileksetil; zatajenje srca

Članak u cijelosti pročitajte u tiskanom izdanju MEDIX, God. 15 Br. 82

The use of angiotensin II type 1 receptor blockers (ARBs) in the treatment of patients with hypertension and congestive heart failure has already been an established clinical practice. Candesartan cilexetil is a recent ARB, more effective than other drugs in the group. It has proven antihypertensive effects comparable to those of calcium channel blockers and a side effect profile similar to that of placebo. In clinical use, when administered as a monotherapy or in combination with diuretics, it effectively controls blood pressure and has beneficial effects on the cardiovascular system. Candesartan cilexetil was tested in the treatment of patients with congestive heart failure not only as a replacement for angiotensin converting enzyme inhibitors (ACEI), but also as additional therapy to ACEI. It was also evaluated in patients with decreased diastolic and preserved systolic function of the left ventricle. In both groups of patients, it significantly reduced cardiovascular complications and hospitalization rates.

Key words:
angiotensin II type 1 receptor blockers; candesartan cilexetil; heart failure; hypertension